CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
carboplatin +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00002474
NCT00002474Phase 2Completed

Phase II Study of High Dose Cyclophosphamide, Mitoxantrone, and Carboplatin With Autologous Bone Marrow Transplantation in Refractory or Relapsed Ovarian Carcinoma

Loyola University·interventional·Posted Jan 27, 2003·Updated May 30, 2013

In Brief

A Phase 2 clinical trial evaluating carboplatin, cyclophosphamide, and 3 other interventions for Ovarian Cancer. Completed, across 1 site.

Detailed Summary

RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, carboplatin, and mitoxantrone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy with autologous bone marrow transplant may allow the doctor to give higher doses of chemotherapy and kill more tumor cells. PURPOSE: This phase II trial is studying how well chemotherapy and autologous bone marrow transplant work in treating patients with refractory or recurrent ovarian cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
1991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 27, 2003
Enrollment StartFeb 1, 1991
Study CompletionOct 1, 2005
TodayJul 2, 2026
Posted 23.4 years ago

Interventions

carboplatindrug

cyclophosphamidedrug

mitoxantrone hydrochloridedrug

autologous bone marrow transplantationprocedure

bone marrow ablation with stem cell supportprocedure